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Abstract
Background: Increasing evidence indicates that tumor endothelial cells (TEC) differ from normal endothelial cells (NEC). Our
previous reports also showed that TEC were different from NEC. For example, TEC have chromosomal abnormality and
proangiogenic properties such as high motility and proliferative activity. However, the mechanism by which TEC acquire a
specific character remains unclear. To investigate this mechanism, we focused on tumor-derived microvesicles (TMV). Recent
studies have shown that TMV contain numerous types of bioactive molecules and affect normal stromal cells in the tumor
microenvironment. However, most of the functional mechanisms of TMV remain unclear.
Methodology/Principal Findings: Here we showed that TMV isolated from tumor cells were taken up by NEC through
endocytosis. In addition, we found that TMV promoted random motility and tube formation through the activation of the
phosphoinositide 3-kinase/Akt pathway in NEC. Moreover, the effects induced by TMV were inhibited by the endocytosis
inhibitor dynasore. Our results indicate that TMV could confer proangiogenic properties to NEC partly via endocytosis.
Conclusion: We for the first time showed that endocytosis of TMV contributes to tumor angiogenesis. These findings offer
new insights into cancer therapies and the crosstalk between tumor and endothelial cells mediated by TMV in the tumor
microenvironment.
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Introduction
Tumor blood vessels have been recognized as an important
target for cancer therapy since Folkman introduced the concept
that tumor growth is dependent on angiogenesis. Tumor
angiogenesis is necessary for solid tumor progression and
metastasis [1]. Tumor blood vessels provide nutrition and oxygen,
promote tumor progression, and serve as gatekeepers for tumor
cells to metastasize to other organs. Therefore, inhibition of tumor
angiogenesis is a promising strategy for the treatment of cancer.
Tumor blood vessels are different from their normal counter-
parts and have altered morphology, altered blood flow, enhanced
leakiness, structural abnormalities in the basement membrane, and
abnormal pericytes [2]. Furthermore, there are many differences
at the molecular and functional levels between tumor endothelial
cells (TEC) and normal EC (NEC) [3,4]. At the molecular level,
TEC have distinct gene expression profiles [5].
We reported that TEC are cytogenetically abnormal [6,7]. In
addition, TEC showed higher migration potential and prolifera-
tion than NEC [8]. These results demonstrated that TEC
maintain distinct biological differences from NEC as observed in
tumor blood vessels in vivo. Furthermore, we reported that TEC
have proangiogenic phenotype. For examples, TEC expressed
high levels of the angiogenesis-related genes vascular endothelial
growth factor (VEGF) and cyclooxygenenase-2 [9,10]. However,
the mechanism of acquisition of TEC abnormality has not been
completely understood.
Recent studies report that crosstalk between tumor cells and
stromal cells are important for tumor progression or acceleration
of tumor malignancy by secreting microvesicles (MVs) [11,12].
MVs have recently attracted attention among researchers of
immune response and embryo development, playing a role in cell-
to-cell communication [13]. MVs are released from various tumor
cells and some progenitors of differentiated cells [14]. Tumor-
derived MVs (TMV) contain bioactive molecules such as
microRNAs (miRNA), mRNAs, and/or proteins inside themselves
[15]. TMV are considered to facilitate extracellular matrix
invasion and immune response evasion [16,17,18]. A few studies
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relationship between TMV uptake and its functions has not been
elucidated, and it remains unclear how TEC are affected by TMV.
In the present study, to investigate the contribution for the
specific phenotype of TEC, we analyzed the effect of TMV on
NEC and the mechanism of their uptake.
Materials and Methods
Cell lines and culture conditions
A375-SM, a super-metastatic human malignant melanoma cell
line, was kindly gifted by Dr. Isaiah J. Fidler (M.D. Anderson
Cancer Center, Houston, TX). The cells were cultured in
Minimum Essential Medium (GIBCO, Grand Island, NY) and
supplemented with 10% fetal bovine serum. NEC were isolated
according to the following method and cultured in a microvascular
endothelial growth medium (Lonza, Basel, Switzerland) in a
humidified atmosphere of 5% CO2 and 95% air at 37uC. Human
microvascular endothelial cells (HMVEC) were purchased (Lonza,
Basel, Switzerland) and cultured in microvascular endothelial
growth medium (Lonza, Basel, Switzerland). Human renal
epithelial cells (hREC) were purchased (Lonza, Basel, Switzerland)
and cultured in renal epithelial cell growth medium (Lonza, Basel,
Switzerland).
Isolation of NEC
NEC were isolated from mouse dermal tissue using a magnetic
activated cell sorting system (Miltenyi Biotec, Tokyo, Japan) with
anti-CD31 antibody as previously described [6–10]. All animal
experiments were performed following the regulation on animal
experimentation of Hokkaido University. This study was approved
by the Animal Care and Use Committee of Hokkaido University
(approval ID: 08-0296). The binding of Bandeiraea simplicifolia
isolectin B4 (BS1-B4 lectin) and the expression of CD31, CD105,
and CD144 indicated a high purity of isolated EC in flow
cytometric analysis. Furthermore, RT-PCR revealed that NEC
expressed CD31, CD105, CD144, VEGF receptor-1, and VEGF
receptor-2 (VEGFR1 and VEGFR2), indicating that NEC
possessed EC characteristics during culture. Isolated EC were
negative for the monocyte marker CD11b and hematopoietic
marker CD45 by RT-PCR. Template-free samples were used as
the negative controls.
RT-PCR
Total RNA was extracted using the RNeasy Micro Kit (Qiagen,
Valencia, CA, USA), and complementary DNA (cDNA) was
synthesized using ReverTra-Plus (Toyobo, Osaka, Japan) as
described previously [6]. cDNA was amplified by PCR and
products were visualized by ethidium bromide staining under
ultraviolet transillumination.
Antibodies and reagents
Rat anti-mouse CD31 antibody and fluorescein isothiocyanate
(FITC)-conjugated anti-mouse CD31 antibody was purchased
from eBioscience (San Diego, CA, USA). FITC-conjugated BS1-
B4 lectin was purchased from Vector Laboratories Burlingame,
CA, USA). PE-conjugated anti-mouse CD31 antibody, anti-mouse
CD105 antibody, rat anti-mouse CD144 antibody, and normal rat
IgG were purchased from BD Pharmingen (San Diego, CA, USA).
Anti-b-actin, total Akt, phospho (Ser473)-Akt, and anti-rabbit
HRP-congujated secondary antibody were obtained from Cell
Signaling Technology (Boston, MA, USA). LY294002 was
obtained from Calbiochem (San Diego, CA, USA) and dynasore
from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Isolation of TMV
TMV were obtained from A375-SM as previously described
[20]. Before isolation of TMV, FBS was ultracentrifuged at
110,000 g for 1 h. Then, A375-SM cultured media was replaced
minimum essential medium supplemented with ultracentrifuged
10% FBS. After incubation for 2 days, the conditioned medium
was collected and centrifuged at 2,000 g for 15 min at 4uCt o
thoroughly remove cellular debris. The supernatant was centri-
fuged again at 110,000 g for 70 min at 4uC. The pellets were
washed with phosphate-buffered saline, and after ultracentrifuga-
tion, were resuspended in phosphate-buffered saline. Protein levels
were determined using the BCA assay from Pierce Chemical Co
(Rockford, IL, USA).
Flow cytometry
For surface phosphatidylserine detection, TMV were resus-
pended in PBS and incubated with annexin V-FITC (Roche,
Indianapolis, IN, USA) and anti-HLA-FITC for 30 min at room
temperature. After washing to remove unbound reagents, size
calibration of TMV was performed using microbeads (Invitrogen,
Carlsbad, CA, USA) Next, TMV were analyzed on a BD FACS
Aria II Flow Cytometer (BD, NJ, USA). Data were analyzed by
Flow Jo (Tree Star, San Carlos, OR, USA).
Scanning Electron Microscopy (SEM)
TMV were incubated on a coverslip at 37uC for 4 h. It was
fixed with 2% glutaraldehyde in PBS. TMV were post fixed for
1 h with 1% osmium tetraoxide in PBS and were dehydrated in
graded ethanol solutions of 50%, 70%, 95%, and 100% before
being placed in an HCP-1 critical point drying machine (Hitachi,
Tokyo, Japan). TMV were sputter-coated with platinum and
palladium before being observed under an S4000 scanning
electron microscope (Hitachi, Tokyo, Japan).
Transmission Electron Microscopy (TEM)
TEM assay was performed as described previously [21]. After
incubation with TMV (50 mg/ml) for 60 min, NEC were immersed
in 2% glutaraldehyde in 0.1 M phosphate buffer for at least 2 h.
The cells were treated with 1% OsO4 solution, dehydrated with a
graded series of ethanol and propylene oxide, and embedded in
epoxy resin. Ultra-thin sections (thickness, 60 nm) were cut, stained
with lead citrate, and examined using HITACHI H-7000 electron
microscope (HITACHI, Tokyo, Japan).
TMV uptake assay
TMV were labeled using the PKH26 red fluorescent labeling
Kit (Sigma-Aldrich, St. Louis, MO, USA) according to the
manufacturer’s instructions. Labeled TMV (50 mg/ml) were
incubated at 37uC for 1 and 24 h. For FACS analysis, the cells
were washed twice and trypsinized. After washing, the cells were
resuspended in PBS containing 2 mM EDTA and 2% FBS. Next,
PKH26 fluorescence in the cells was analyzed by FACS.
To determine PKH26-labeled TMV localization in NEC, the
cells were fixed with 4% paraformaldehyde, washed, and stained
with MFP488-phalloidin (MoBiTec, Go ¨ttingen, Germany) and
49,6-diamidino-2-phenylindole (Roche, Indianapolis, IN, USA).
PKH26-labeled TMV localization by ECs was determined using
an FV10i confocal laser scanning microscope (Olympus, Tokyo,
Japan).
Random motility assay
Cells were plated on glass bottom dishes coated with poly-L-
lysine (Matsunami, Osaka, Japan). After overnight incubation, the
Tumor-Derived Microvesicles Enhance Angiogenesis
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LY294002 (80 mM) for 30 min. Cell movements were monitored
with or without TMV (50 mg/ml) under an FV10i microscope
(Olympus, Tokyo, Japan) at 10 min intervals. Velocity was
determined by tracking the positions of cell nuclei using ImageJ
(NIH, Bethesda, MD, USA). Migrated distance was integrated and
divided by monitored time (12 h).
Tube formation assay
Diluted Matrigel (BD Biosciences, San Jose, CA, USA) was
transferred to a glass bottom dish and incubated at 37uC for
30 min to allow the matrix solution to solidify. Cells were
harvested and resuspended in appropriate media and preincubat-
ed with or without dynasore (50 mM) and LY294002 (80 mM) for
30 min. Cells were then seeded at a density of 1610
5 cells per well
with or without TMV (50 mg/ml), followed by incubation at 37uC
for 12 h. Tube formation was observed using an inverted
microscope and the experimental results were recorded at different
times. The mean tube length was calculated using ImageJ.
Western blotting
Western blot analysis was performed using antibodies specific to
phosphorylated-Akt, total-Akt and HRP-conjugated secondary
antibody as described previously [22]. Cells and TMV were lysed
in RIPA buffer [50 mM Tris-HCl (pH=7.4), 150 mM NaCl,
1 mM EDTA, 1% NP-40, 0.1% SDS, 0.5% sodium deoxycholate,
and 1 mM Na3VO4] for 10 min on ice, and the lysate was
clarified by centrifugation. Samples were electrophoresed on 10%
polyacrylamide gels and transferred to Immobilon-P membranes
(Millipore, Bradford, MA). The membranes were blocked for
60 min in TBS containing 5% skimmed dry milk and 0.1% Tween
20, and then incubated for overnight at 4uC with primary
antibodies followed by incubation with HRP-conjugated secondly
antibodies. Signals were developed using the ECL Western
Blotting Detection Reagent (GE Healthcare, Little Chalfont,
UK) and detected using an LAS-4000 mini image analyzer
(FUJIFILM, Tokyo, Japan).
Statistical analysis
Mean 6standard error (SE) values were compared using one-
way ANOVA with Tukey-Kramer multiple comparison testing.
When only two groups were compared, a two-sided Student’s t-test
was used.
Results
Isolation and culture of NEC
NEC were isolated from mouse dermal tissue using a magnetic
cell sorting system as described above. Flow cytometric analysis
revealed the binding of BS1-B4 lectin and the expression of CD31,
CD105, and CD144 in NEC (Figure 1A). RT-PCR revealed that
NEC expressed CD31, CD105, CD144, VEGFR1, and VEGFR2,
indicating that EC characteristics were present even during
culture. Isolated EC were negative for the monocyte marker
CD11b and hematopoietic marker CD45 by RT-PCR. As the
negative controls, template-free samples were used (Figure 1B).
These results showed a high purity of isolated NEC.
TMV characterization
It has not been established conclusively how TEC acquire their
abnormality in a tumor microenvironment. There are several
reports that MVs secreted from malignant tumor cells (tumor-
derived MVs: TMV) affect surrounding normal cells [23,24]. In
addition, we have found that a tumor-conditioned medium (tumor
CM) induced some phenotypic change in such as enhanced
motility (Figure S1A) and proliferation (Figure S1B). Furthermore
tumor CM inhibited apoptosis induced by serum starvation in
NEC (Figure S1C). Thus, we speculated that TMV contained in
tumor-conditioned medium may cause phenotypic changes in
ECs. To investigate how TMV contribute to the phenotypic
change in NEC, we analyzed the effect of TMV secreted from a
high-metastatic melanoma cell line, A375-SM cells.
TMV reportedly have a size of less than a few micrometers.
Flow cytometric analysis of human TMV was performed to
determine the size of TMV. Most isolated TMV were found to be
around the forward and side scatter signal corresponding to 1-mm
beads by flow cytometry, using micro beads as internal size
standards (Figure 1C).
Scanning electron microscopy showed that TMV had a
spheroid morphology less than 1 mm similar to flow cytometric
assay (Figure 1D), although they were heterogenous in size.
Various reports have suggested that the surface of TMV express
various cell membrane components, such as HLA originated from
host cells [25] and phosphatidylserine [26], which consist of the
inner leaflet of the cell membrane.
Isolated TMV were analyzed by flow cytometry using annexin
V, which binds to phosphatidylserine, and anti-human HLA.
These results suggested that TMV expressed phosphatidylserine
and HLA (Figure 1E and 1F). Furthermore, western blotting
analysis revealed TMV contains microvesicles markers, b-actin
[27] and HLA (Figure 1G).
TMV were taken up by NEC
A previous report indicates the possibility that protein and/or
nucleic acids (mRNAs, miRNA) are packaged into MVs and can
be taken up by cells, acting as biomolecules [14,20,28,29]. To
elucidate how TMV are taken up by NEC, TMV-treated NEC
were analyzed by flow cytometry and confocal laser scanning
microscopy.
After treatment with PKH26-labeled TMV for 1 and 24 h,
NEC were analyzed for their fluorescent intensity using flow
cytometry (Figure 2A). The fluorescent signal intensity was
stronger in NEC after treatment with TMV for 24 h than after
treatment for 1 h. Of note, confocal laser scanning microscopy
analysis revealed that PKH26-labeled TMV were observed in
cytoplasm after 1 and 24 h (Figure 2B). These results suggest that
TMV were taken up by NEC.
Then, we hypothesized that TMV uptake is dependent on
endocytosis because many types of extracellular fluids and
nutrients are taken up by this process. To confirm this hypothesis,
we performed the TMV uptake assay with low temperature
treatment. Since endocytosis is energy-dependent, low tempera-
ture treatment is a common method for inhibition of endocytosis
[30]. TMV uptake was inhibited at low temperature (Figure 2C),
thus confirming that TMV uptake is endocytosis dependent.
Furthermore, small particles were colocalized at engulfed plasma
membrane by transmission electron microscopy (Figure 2D).
These results suggested that TMV were taken up via endocytosis.
In addition, staining NEC with LysoTracker revealed that some
TMV are transported to the lysosome after endocytosis (Figure 2E).
Endocytosis requires a small GTPase dynamin, which pinches
off endocytic vesicles from the cytomembrane [31]. Thus, we
analyzed the effect of a specific dynamin inhibitor, dynasore, on
TMV uptake. Flow cytometric analysis showed that dynasore
inhibited TMV uptake in a dose-dependent manner (Figure 2F).
TMV-treated NEC were observed by confocal laser scanning
microscopy after treatment with/without dynasore. The resulting
images are shown (Figure 2G).
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endocytosis.
TMV-induced proangiogenic property in NEC was
inhibited by the endocytosis inihibitor
We have shown that TEC have higher motility, which is
important for angiogenesis, than NEC [8]. To analyze the effects
of TMV on NEC, they were treated with TMV (50 mg/ml) for
12 h, and the random motility of cells was traced for 12 h using
time-lapse videoscopy (Figure 3A).
Random motility of NEC increased significantly on TMV
treatment compared with the control (P,0.01). When NEC were
treated with the endocytosis inhibitor dynasore, TMV could not
enhance NEC motility (Figure 3B).
Next, we investigated the effect of TMV on the angiogenic
property of NEC by in vitro tube formation assay with/without
dynasore. Representative data are shown (Figure 3C). The tube
length of the capillary-like structure was calculated by ImageJ.
After incubation with or without TMV (50 mg/ml) for 12 h, the
total tube length was 1.37-fold longer in TMV-treated NEC than
that in the control NEC (Figure 3D). However, dynasore
suppressed TMV-stimulated tube formation. By apoptosis assay,
dynasore (50 uM) did not show apoptotic changes in NEC (Figure
S2). The inhibitory effects of dynasore on NEC were not caused by
cytotoxicity. These results indicate that TMV uptake induces
proangiogenic properties in NEC, at least in part via endocytosis.
TMV activate the phosphoinositide 3-kinase (PI3K)/Akt
pathway via endocytosis
Akt phosphorylation is known to be involved in EC migration
and tube formation [32]. From the results mentioned above, we
hypothesized that TMV could activate Akt phosphorylation in
NEC and analyzed the effect of TMV on Akt phosphorylation in
NEC by western blotting. After treatment with TMV for 10 min,
Akt phosphorylation was enhanced in NEC (Figure 4A). It is well
known that Akt is regulated by PI3K, but recently, several reports
suggest that Akt is also activated in a PI3K-independent manner
[33].
Figure 1. Characterization of isolated normal endothelial cells (NEC) from mice. (A) Representative flow cytometric analysis of NEC
showing the expression of the endothelial markers CD31, CD105, CD144, and BS1-B4 lectin (mouse endothelial marker) (white area). Control levels
with normal isotype IgG are shown in the gray area. Binding of BS1-B4 lectin and the expression of CD31, CD105, and CD144 revealed the high purity
of the isolated NEC by FACS. (B) RT-PCR revealed that NEC expressed CD31, CD105, CD144, vascular endothelial growth factor receptor-1, 2 (VEGFR1
and VEGFR2) and not the monocyte marker CD11b and the hematopoietic marker CD45. To demonstrate that NEC were purified without any blood
cell contamination, we also performed RT-PCR in mouse peripheral blood mononuclear cells (PBMC). Negative control was performed with template-
free samples. (C) A375-SM cultured medium are analyzed by flow cytometry. The figure shows the forward and side scatter plot of the medium. A375-
SM cells were cultured for 48 h. (D) Isolated TMV were observed by electron scanning microscopy. For sample preparation, TMV were coated on a
glass cover for 4 h. (E, F) Flow cytometric analysis of TMV showing expression of HLA and phosphatidylserine (white area). (G) Western blotting
analysis of TMV showing expression of HLA and b-actin. Same amount of proteins were loaded. These results indicate that some TMV might be
shedding microvesicles derived from tumor plasma membrane.
doi:10.1371/journal.pone.0034045.g001
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is dependent on PI3K. NEC were treated with LY294002 (20 mM)
for 2 h, followed by stimulation with TMV. Akt phosphorylation was
examined by western blotting. It was determined that LY294002
inhibited TMV-induced Akt phosphorylation (Figure 4B), which
suggests that TMV activate the PI3K/Akt pathway in NEC.
Next, to investigate the activation of the PI3K/Akt pathway by
TMV, we used dynasore. After NEC were pretreated with
Figure 2. NEC take up TMV into cytoplasm depending on endocytosis. (A) Fluorescent intensity of TMV-treated NEC were measured by flow
cytometry. Before treatment, TMV were stained with PKH26 dye. A dashed histogram shows NEC treated with TMV for 1 hr and an open histogram
shows NEC treated with TMV for 24 h. (B) Fluorescent images of NEC treated with TMV for 1 and 24 h are shown. Green: F-actin, red: PKH26 -labeled
TMV. Bar=20 mm. (C) Flow cytometric analysis of TMV-treated NEC under low temperature. Filled histogram: 4uC, dashed histogram: room
temperature, opened histogram: 37uC. NEC were pretreated in each temperature for 30 min and treated with PKH26 -labeled TMV for 30 min under
each temperature. (D) The cells were incubated with TMV (50 mg/ml) for 60 min and fixed. The TEM images revealed that small particles were
colocalized at engulfed plasma membrane in TMV-treated NEC (arrow). It was not observed in untreated-control. Bar=2 mm. (E) TMV localization after
endocytosis in NEC. NEC were stained with LysoTrakcer, fluorescent lysosome probe. Green: lysosome, red: PKH26 -labeled TMV. Bar=10 mm. This
result suggests that TMV were taken up via endocytosis. Endocytosis inhibitor blocked TMV uptake. (F) NEC were incubated with or without dynasore
(1, 10, 20, 30 mM) for 30 min before treatment with PKH26-labeled TMV. After treatment with TMV for 15, 30, and 60 min, fluorescent intensity were
measured by flow cytometry. TMV uptake ratio were compared with dynasore-treated NEC with untreated NEC. (G) Fluorescent images of NEC with
or without dynasore (20 mM) are shown. Green: F-actin, red: PKH26 -labeled TMV. Bar=20 mm.
doi:10.1371/journal.pone.0034045.g002
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tion (Figure 4C). These results indicate that TMV uptake via
endocytosis results in activation of PI3K/Akt.
TMV-induced proangiogenic phenotype is mediated by
PI3K/Akt
In order to analyze involvement of PI3K/Akt pathway in cell
motility and tube formation enhanced by TMV, the PI3K
inhibitor, LY294002 was used. TMV did not stimulate cell
motility when NEC was treated with LY294002 (Figure 5A).
Furthermore, LY294002 inhibited tube formation enhanced by
TMV (Figure 5B). These results indicate that TMV induced
proangiogenic phenotype on NEC through PI3K activation, at
least in part.
Discussion
The aim of this study was to investigate how TMV affect
phenotypic changes in EC in a tumor microenvironment. This
study yielded several results:
(1) TMV are taken up by NEC via endocytosis.
(2) TMV promote cell motility, tube formation, and Akt
phosphoarylation in NEC.
(3) TMV endocytosis is required for induction of the proangio-
genic phenotype in EC.
In this study, we tried to isolate MV from normal cells as normal
control. However, normal endothelial cells (HMVEC) and normal
epithelial cells (hREC) secreted few amount of microvesicles
compared to melanoma cells (Figure S3), consisting with the
another report [34]. These results suggested that proangiogenic
phenotypes as shown in this study are caused by TMV, not by MV
from normal cells.
We previously reported that TEC had higher motility than
NEC [8], and Akt phosphorylation levels in TEC were higher than
those in NEC [35]. In addition, we observed that tumor-
conditioned medium (tumor CM) induced enhanced cell growth
or anti-apoptotic phenotype to NEC (Figure S1B, C). However, it
remains unclear which factors contained in tumor-conditioned
medium affect phenotypic changes in NEC. Despite this
uncertainty, our results indicate that the uptake of TMV, which
are contained in tumor-conditioned medium, induces phenotypic
changes in NEC.
Although TMV are classified by size and several markers, their
whole character have not been cleared, yet. In this study, isolated
TMV had a wide range of size distribution observed by SEM and
flow cytometry. TMV expressed HLA and b-actin, which are the
markers for shedding microvesicle derived from tumor plasma
membrane [36]. In addition, some TMV were smaller than
200 nm, suggesting that some of them might be exosomes. From
these results, TMV have heterogeneous population. Other
classifications are reported such as apoptotic bodies [19],
microparticles [37], lipoprotein particles [38]. However, the
Figure 3. TMV promote random motility and tube formation in NEC. Time-lapse observation revealed that TMV promote random motility in
NEC. When treated by the endocytosis inhibitor dynasore, cell motility was not stimulated anymore. (A) Migrated trajectories of TMV-treated NEC
(with/without 50 mM dynasore) were plotted and velocity was calculated using ImageJ. (B) The results are presented as mean velocities 6 SE (DMSO;
n=15, DMSO+TMV; n=15, dynasore; n=15, dynasore+TMV; n=15). *P,0.01. TMV also promote tube formation in NEC. Dynasore canceled increase
of tube formation even in NEC cultured with TMV. (C) Phase-contrast images of control and TMV-treated NEC (with/without 50 mM dynasore) cultured
on a matrigel. Bar=100 mm. Capillary-like structure enhanced with TMV. Total length of capillary-like tubes was analyzed using ImageJ. (D) The results
are presented as mean tube length per field 6 SE. (DMSO; n=10, TMV; n=10, dynasore; n=10, dynasore+TMV; n=10). *P,0.01.
doi:10.1371/journal.pone.0034045.g003
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elucidated.
There have been a few studies about the uptake on TMV by
normal cells [14,19]. The mechanism of the uptake of TMV has
been controversial with regard to both endocytosis and membrane
fusion [11]. In our study, the TEM revealed that small particles
were colocalized at engulfed plasma membrane. It was not
observed in untreated-NEC. In addition, TMV localized in the
lysosome and dynasore inhibited the uptake of TMV by NEC.
Thus, it was suggested that some membrane trafficking machinery,
such as endosomal transport, may be used for TMV uptake [30].
These results showed that TMV are taken up via endocytosis.
However, we did not investigated whether TMV are taken up via
membrane fusion or not. Further study is needed.
Several reports have demonstrated that TMV can activate Akt
phosphorylation [12,39]. Recently, it was reported that the PI3K/
Akt pathway affects EC motility and tube formation through the
reorganization of actin cytoskeleton [40,41]. We for the first time
showed that cell motility and tube formation were enhanced via
the PI3K/Akt pathway in normal cells by the uptake of TMV.
There have also been several reports that TMV transfer
bioactive molecules to recipient cells [14,20,28,29]. It is well
known that receptor tyrosine kinase activation via growth factors
regulates the PI3K/Akt pathway [42]. First, we analyzed the
contents of TMV by cytokine array. However, there were minimal
growth factors in TMV. This indicates that TMV-induced PI3K/
Akt activation may not be caused by growth factors/receptor
activation.
To investigate if TMV-induced motility of NEC is regulated in
an autocrine manner, NEC was treated by TMV in bottom
chamber of transwell. Migration assay was performed to analyze
whether TMV-NEC can attract NEC from upper chamber in an
autocrine manner or not (Figure S4A). As a result, the number of
NEC which migrated toward the bottom chamber did not increase
Figure 4. TMV activate the PI3K/Akt pathway. (A) TMV activated Akt in NEC. NEC were incubated with TMV (50 mg/ml) for the indicated time
periods, and phosphorylated-Akt (p-Akt) and total-Akt (t-Akt) levels were determined in cell lysates by immunoblotting. Lower; Relative
phosphorylated-Akt levels (p-Akt/t-Akt). (B) LY294002 inhibited Akt phosphorylation induced by TMV. NEC were preincubated with or without
LY294002 (20 mM) for 2 h, then with or without TMV (50 mg/ml) for 20 min. Relative phosphorylated-Akt levels were quantified by immunoblotting.
(C) The endocytosis inhibitor blocked Akt phosphorylation induced by TMV. NEC were preincubated with or without dynasore (20, 40 mM) for 30 min,
and then with or without TMV (50 mg/ml) for 20 min. Relative phosphorylated-Akt levels were quantified by immunoblotting.
doi:10.1371/journal.pone.0034045.g004
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tion in NEC is not regulated in an autocrine manner.
Regarding with bioactive molecules in TMV, the possible
bioactive molecules in TMV are phospholipids. Phosphatidylser-
ine and sphingomyelin, which are the components of the
membrane of TMV, activate Akt phosphorylation [43]. Moreover,
other reports have indicated that the Ras-PI3K pathway is
activated by endocytosis of virus micro particles [44]. Taken
together, TMV endocytosis itself may also be important for
activation of the signaling pathway in EC in tumor microenvi-
ronment.
In this study, we for the first time demonstrated that TMV are
taken up by NEC via endocytosis. TMV uptake confers
proangiogenic properties on NEC. Inhibiting TMV endocytosis
may lead to the development of a useful prevention strategy
against tumor angiogenesis.
Supporting Information
Figure S1 Tumor-conditioned medium activates NEC.
A375-SM cells were cultured in MEM (0.5% FBS supplemented).
After two days, conditioned medium was centrifuged at 2,000 g to
remove cells and debris. Random motility, cell proliferation and
apoptosis were analyzed in NEC with NEC conditioned medium
(NEC CM) or tumor conditioned medium (tumor CM). (A)
Random motility was measured by time-lapse observation. Mean
velocities are presented 6 SE (NEC CM; n=15, tumor CM;
n=15, p,0.01). Tumor CM enhanced motility in NEC. (B) NEC
proliferation was measured using MTS assay kit (Promega, Tokyo,
Japan). Mean MTS activity are plotted (n=4). Cell proliferation
was stimulated by Tumor CM. (C) The cells were stained with the
Annexin-V-FLUOS Staining kit (Roche, Indianapolis, IN, USA)
and were analyzed by flow cytometry (NEC-CM; n=2, tumor
CM; n=4, bar=standard deviation, p,0.05). The percentages of
dead cells decreased when NEC were treated by tumor CM.
(TIF)
Figure S2 Analysis of cytotoxicity of Dynasore. Cytotox-
icity of dynasore was measured by apoptosis assay kit. NEC were
treated with a various concentration of dynasore for 16 h. The
cells were analyzed by flow cytometry. Dynasore was not cytotoxic
to NEC at the concentration of 50 mM, that was used in our study.
(TIF)
Figure S3 Normal cells secrete small amounts of MV.
A375-SM, HMVEC and hREC were seeded with 50% con-
fluency. After two days, cells were trypsinized and total cell
number were counted respectively and MV-derived from each cell
lines were isolated as mentioned below. (A) Protein amount of each
MV were measured by BCA protein assay kit. Then, secreted
amount of MV per single cell were estimated. The amount of MV
secreted by tumor and normal cell was analyzed. Under same
conditions, the amounts of normal cell derived MV were little
(HMVEC; 10 mg, hREC; 3 mg), compared with that of tumor cells
(A375-SM; 435 mg). Secreted amount of MV per single cell (pg/
cell) were presented. (B) MV numbers isolated from each
conditioned medium was counted using flow cytometry. It was
suggested that normal cell secreted little amount of MV. Counted
numbers of MV in each conditioned medium are presented.
(TIF)
Figure S4 TMV-induced migration was not regulated in
an autocrine manner. To discuss how TMV enhance motility in
NEC, transwell assay (Corning, Tokyo, Japan) was performed
according to manufacturer’s protocol. (A) Briefly, NEC were seeded
on bottom chamber (1610
4cells/cm
2).After4 h,adheredNECwere
treated with or without TMV (50 mg/ml) in bottom chamber. Then,
NEC were seeded on upper chamber (1610
5 cells/ml). Twelve hours
later, NEC were fixed with 10% formalin and stained with Mayer’s
Hematoxylin solution. (B) Migrated NEC numbers towards super-
natant from NEC treated with or without TMV were counted
(untreated; n=12, with TMV; n=12). NEC did not migrate towards
supernatant from TMV-treated NEC in bottom chamber.
(TIF)
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Figure 5. LY294002 inhibited TMV-promoted random motility and tube formation in NEC. (A) When treated by the PI3K inhibitor
LY294002, cell motility was not stimulated by TMV (50 mg/ml) anymore. The results are presented as mean velocities 6 SE (DMSO; n=15,
DMSO+TMV; n=15, LY294002; n=15, LY294002+TMV; n=15). *P,0.01. (B) In addition, LY294002 suppressed increase of tube formation in NEC
treated by TMV (50 mg/ml). The results are presented as mean tube length per field 6 SE. (DMSO; n=10, DMSO+TMV; n=10, LY294002; n=10,
LY294002+TMV; n=10). *P,0.01. These results indicate that TMV-induced proangiogenic phenotype is mediated by PI3K/Akt pathway, at least in
part.
doi:10.1371/journal.pone.0034045.g005
Tumor-Derived Microvesicles Enhance Angiogenesis
PLoS ONE | www.plosone.org 8 March 2012 | Volume 7 | Issue 3 | e34045References
1. Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med
285: 1182–1186.
2. Jain RK (2003) Molecular regulation of vessel maturation. Nat Med 9: 685–693.
3. McDonald DM, Baluk P (2002) Significance of blood vessel leakiness in cancer.
Cancer Res 62: 5381–5385.
4. Morikawa S, Baluk P, Kaidoh T, Haskell A, Jain RK, et al. (2002) Abnormalities
in pericytes on blood vessels and endothelial sprouts in tumors. Am J Pathol 160:
985–1000.
5. St Croix B, Rago C, Velculescu V, Traverso G, Romans KE, et al. (2000) Genes
expressed in human tumor endothelium. Science 289: 1197–1202.
6. Hida K, Hida Y, Amin DN, Flint AF, Panigrahy D, et al. (2004) Tumor-
associated endothelial cells with cytogenetic abnormalities. Cancer Res 64:
8249–8255.
7. Akino T, Hida K, Hida Y, Tsuchiya K, Freedman D, et al. (2009) Cytogenetic
abnormalities of tumor-associated endothelial cells in human malignant tumors.
Am J Pathol 175: 2657–2667.
8. Matsuda K, Ohga N, Hida Y, Muraki C, Tsuchiya K, et al. (2010) Isolated
tumor endothelial cells maintain specific character during long-term culture.
Biochem Biophys Res Commun 394: 947–954.
9. Kurosu T, Ohga N, Hida Y, Maishi N, Akiyama K, et al. (2011) HuR keeps an
angiogenic switch on by stabilising mRNA of VEGF and COX-2 in tumour
endothelium. Br J Cancer 104: 819–829.
10. Muraki C, Ohga N, Hida Y, Nishihara H, Kato Y, et al. (2011) Cyclooxygenase-
2 inhibition causes antiangiogenic effects on tumor endothelial and vascular
progenitor cells. Int J Cancer.
11. Muralidharan-Chari V, Clancy JW, Sedgwick A, D’Souza-Schorey C (2010)
Microvesicles: mediators of extracellular communication during cancer
progression. J Cell Sci 123: 1603–1611.
12. Antonyak MA, Li B, Boroughs LK, Johnson JL, Druso JE, et al. (2011) Cancer
cell-derived microvesicles induce transformation by transferring tissue transglu-
taminase and fibronectin to recipient cells. Proc Natl Acad Sci U S A 108:
4852–4857.
13. Ratajczak J, Wysoczynski M, Hayek F, Janowska-Wieczorek A, Ratajczak MZ
(2006) Membrane-derived microvesicles: important and underappreciated
mediators of cell-to-cell communication. Leukemia 20: 1487–1495.
14. Hong BS, Cho JH, Kim H, Choi EJ, Rho S, et al. (2009) Colorectal cancer cell-
derived microvesicles are enriched in cell cycle-related mRNAs that promote
proliferation of endothelial cells. BMC Genomics 10: 556.
15. Cocucci E, Racchetti G, Meldolesi J (2009) Shedding microvesicles: artefacts no
more. Trends Cell Biol 19: 43–51.
16. Dolo V, Ginestra A, Cassara D, Ghersi G, Nagase H, et al. (1999) Shed
membrane vesicles and selective localization of gelatinases and MMP-9/TIMP-1
complexes. Ann N Y Acad Sci 878: 497–499.
17. Ginestra A, La Placa MD, Saladino F, Cassara D, Nagase H, et al. (1998) The
amount and proteolytic content of vesicles shed by human cancer cell lines
correlates with their in vitro invasiveness. Anticancer Res 18: 3433–3437.
18. Valenti R, Huber V, Iero M, Filipazzi P, Parmiani G, et al. (2007) Tumor-
released microvesicles as vehicles of immunosuppression. Cancer Res 67:
2912–2915.
19. Kosaka N, Iguchi H, Ochiya T (2010) Circulating microRNA in body fluid: a
new potential biomarker for cancer diagnosis and prognosis. Cancer Sci 101:
2087–2092.
20. Skog J, Wurdinger T, van Rijn S, Meijer DH, Gainche L, et al. (2008)
Glioblastoma microvesicles transport RNA and proteins that promote tumour
growth and provide diagnostic biomarkers. Nat Cell Biol 10: 1470–1476.
21. Kitahara S, Morikawa S, Shimizu K, Abe H, Ezaki T (2010) Alteration of
angiogenic patterns on B16BL6 melanoma development promoted in Matrigel.
Med Mol Morphol 43: 26–36.
22. Ohga N, Hida K, Hida Y, Muraki C, Tsuchiya K, et al. (2009) Inhibitory effects
of epigallocatechin-3 gallate, a polyphenol in green tea, on tumor-associated
endothelial cells and endothelial progenitor cells. Cancer Sci 100: 1963–1970.
23. Wysoczynski M, Ratajczak MZ (2009) Lung cancer secreted microvesicles:
underappreciated modulators of microenvironment in expanding tumors.
Int J Cancer 125: 1595–1603.
24. Hood JL, San RS, Wickline SA (2011) Exosomes released by melanoma cells
prepare sentinel lymph nodes for tumor metastasis. Cancer Res 71: 3792–3801.
25. Baj-Krzyworzeka M, Szatanek R, Weglarczyk K, Baran J, Urbanowicz B, et al.
(2006) Tumour-derived microvesicles carry several surface determinants and
mRNA of tumour cells and transfer some of these determinants to monocytes.
Cancer Immunol Immunother 55: 808–818.
26. Lima LG, Chammas R, Monteiro RQ, Moreira ME, Barcinski MA (2009)
Tumor-derived microvesicles modulate the establishment of metastatic melano-
ma in a phosphatidylserine-dependent manner. Cancer Lett 283: 168–175.
27. Gyorgy B, Szabo TG, Pasztoi M, Pal Z, Misjak P, et al. (2011) Membrane
vesicles, current state-of-the-art: emerging role of extracellular vesicles. Cell Mol
Life Sci 68: 2667–2688.
28. Pegtel DM, Cosmopoulos K, Thorley-Lawson DA, van Eijndhoven MA,
Hopmans ES, et al. (2010) Functional delivery of viral miRNAs via exosomes.
Proc Natl Acad Sci U S A 107: 6328–6333.
29. Kosaka N, Iguchi H, Yoshioka Y, Takeshita F, Matsuki Y, et al. (2010) Secretory
mechanisms and intercellular transfer of microRNAs in living cells. J Biol Chem
285: 17442–17452.
30. Khalil IA, Kogure K, Akita H, Harashima H (2006) Uptake pathways and
subsequent intracellular trafficking in nonviral gene delivery. Pharmacol Rev 58:
32–45.
31. Macia E, Ehrlich M, Massol R, Boucrot E, Brunner C, et al. (2006) Dynasore, a
cell-permeable inhibitor of dynamin. Dev Cell 10: 839–850.
32. Weng L, Enomoto A, Ishida-Takagishi M, Asai N, Takahashi M (2010) Girding
for migratory cues: roles of the Akt substrate Girdin in cancer progression and
angiogenesis. Cancer Sci 101: 836–842.
33. Cohen MB, Rokhlin OW (2009) Mechanisms of prostate cancer cell survival
after inhibition of AR expression. J Cell Biochem 106: 363–371.
34. Camussi G, Deregibus MC, Bruno S, Grange C, Fonsato V, et al. (2011)
Exosome/microvesicle-mediatedepigeneticreprogrammingofcells.AmJCancer
Res 1: 98–110.
35. Ohga N, Ishikawa S, Maishi N, Akiyama K, Hida Y, et al. (2012) Heterogeneity
of Tumor Endothelial Cells Comparison between Tumor Endothelial Cells
Isolated from High- and Low-Metastatic Tumors. Am J Pathol.
36. Meckes DG, Jr., Raab-Traub N (2011) Microvesicles and viral infection. J Virol
85: 12844–12854.
37. Martinez MC, Tesse A, Zobairi F, Andriantsitohaina R (2005) Shed membrane
microparticles from circulating and vascular cells in regulating vascular function.
Am J Physiol Heart Circ Physiol 288: H1004–1009.
38. Neumann S, Coudreuse DY, van der Westhuyzen DR, Eckhardt ER,
Korswagen HC, et al. (2009) Mammalian Wnt3a is released on lipoprotein
particles. Traffic 10: 334–343.
39. Al-Nedawi K, Meehan B, Kerbel RS, Allison AC, Rak J (2009) Endothelial
expression of autocrine VEGF upon the uptake of tumor-derived microvesicles
containing oncogenic EGFR. Proc Natl Acad Sci U S A 106: 3794–3799.
40. Kitamura T, Asai N, Enomoto A, Maeda K, Kato T, et al. (2008) Regulation of
VEGF-mediated angiogenesis by the Akt/PKB substrate Girdin. Nat Cell Biol
10: 329–337.
41. Wang FZ, Fei HR, Li XQ, Shi R, Wang DC (2011) Perifosine as potential anti-
cancer agent inhibits proliferation, migration, and tube formation of human
umbilical vein endothelial cells. Mol Cell Biochem.
42. Wickenden JA, Watson CJ (2010) Key signalling nodes in mammary gland
development and cancer. Signalling downstream of PI3 kinase in mammary
epithelium: a play in 3 Akts. Breast Cancer Res 12: 202.
43. Kim CW, Lee HM, Lee TH, Kang C, Kleinman HK, et al. (2002) Extracellular
membrane vesicles from tumor cells promote angiogenesis via sphingomyelin.
Cancer Res 62: 6312–6317.
44. Fujioka Y, Tsuda M, Hattori T, Sasaki J, Sasaki T, et al. (2011) The Ras-PI3K
signaling pathway is involved in clathrin-independent endocytosis and the
internalization of influenza viruses. PLoS One 6: e16324.
Tumor-Derived Microvesicles Enhance Angiogenesis
PLoS ONE | www.plosone.org 9 March 2012 | Volume 7 | Issue 3 | e34045